Due to the universal expression of CD22 in B cell ALL cells, new strategies to improve CAR T cell outcomes may include CAR-T cells directed against CD22 [159], and CD19/CD22 dual-targeted constructs [160, 161]. Here, CD19 is linked to acute lymphoblastic leukemia.